Apnimed Stock Surges 56% Amid Growing Interest in Sleep-Related Breathing Diseases

Apnimed, Inc., a clinical-stage company focused on oral therapies for sleep-related breathing diseases, has seen its stock price surge by 56.25% with an increase of $9.00 since the market last closed.

The stock closed at $25.00 and has dropped $2.48 in after-hours trading.

Apnimed was founded in 2017 by Lawrence G. Miller, Barry Wohl, and Luigi Taranto Montemurro and is headquartered in Cambridge, MA.